UBS Group Has Lowered Expectations for Telix Pharmaceuticals (NASDAQ:TLX) Stock Price

Telix Pharmaceuticals (NASDAQ:TLX) had its target price reduced by research analysts at UBS Group from $23.00 to $20.00 in a research note issued on Tuesday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 95.89% from the company’s current price.

Several other equities analysts have also commented on the company. Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. William Blair reiterated an “outperform” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Citigroup started coverage on Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a “buy” rating and a $22.00 target price for the company. HC Wainwright dropped their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Stock Down 6.6%

Telix Pharmaceuticals stock opened at $10.21 on Tuesday. The stock has a fifty day moving average price of $11.57 and a 200 day moving average price of $14.98. Telix Pharmaceuticals has a 52 week low of $8.93 and a 52 week high of $30.36. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the second quarter worth about $213,000. Jane Street Group LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $564,000. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $975,000. Pier Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $3,037,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.